- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02824445
To Evaluate the Efficacy of EEG-guided Magnetic Resonant Therapy in War Veterans With Posttraumatic Stress Disorder
December 28, 2019 updated by: Jianzhong Zhang, 72nd Medical Group, Tinker Air Force Base
A Pilot Study to Evaluate the Efficacy of EEG/ECG-guided Magnetic Resonant Therapy (MeRT) in War Veterans With Posttraumatic Stress Disorder (PTSD) at Tinker and MacDill Air Force Bases
After 13 years of war, PTSD has become pervasive in service members.
Traditionally it is evaluated by PTSD Checklist Military Version (PCL-M) and treated with cognitive processing therapy, prolonged exposure therapy and medication management with limited success.
Repetitive Transcranial Magnetic Stimulation (TMS) has shown efficacy for improving individual cognitive function in the past decades, both in healthy population and in patients with depression.
TMS has been approved by the FDA in treatment of major depressive disorder and migraine headaches.
Magnetic EEG guided Resonant Treatment (MeRT) is a form of individualized TMS based on member's EEG/ECG input.
Investigators propose to use MeRT to treat veterans with war-related PTSD, a syndrome that includes depressive and anxious symptoms; it is likely that MeRT (namely TMS) will be beneficial and comparable to or better than the current FDA approved methods for treating PTSD.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
13
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73145
- 72d Medical Group
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have diagnosis of combat-related PTSD by DSM-V criteria, diagnosed via clinical interview by psychologist or psychiatrist (note: combat pilots of remotely piloted aircraft are included)
- PCL-M score > 45
- Age between 18 and 55 years (at day of informed consent)
- Willing and able to adhere to the treatment schedule and all required study visits.
- Must be clinically stable for at least 30 days on or off any PTSD medication before the trial treatment
Exclusion Criteria:
Individuals diagnosed by the Investigator with the following conditions (current unless otherwise stated):
- History of open skull traumatic brain injury
- History of clinically significant seizure disorder
Individuals with a clinically defined neurological disorder including, but not limited to:
- Any condition likely to be associated with increased intracranial pressure
- Space occupying brain lesion
- History of cerebrovascular accident
- Cerebral aneurysm
- Abnormalities that indicate risk of seizure, i.e., focal or general slowing or spikes during EEG recording
- Any type of rTMS treatment within 3 months prior to the screening visit
- Currently under antipsychotic medication treatment
- Intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, stents, or electrodes) or any other metal object within or near the head, excluding the mouth, which cannot be safely removed
- Clinically significant abnormality or clinically significant unstable medical condition that in the Investigator's judgment might pose a potential safety risk to the subject or limit interpretation of the trial results
- Clinically significant medical illness, including any uncontrolled thyroid disorders, hepatic, cardiac, pulmonary and renal malfunctioning
- Any condition which in the judgment of the investigator would prevent the subject from completion of the study
- Inability to acquire a clinically satisfactory EEG/ECG on a routine basis
- Grossly abnormal electrolyte or cell blood count panels suggestive of other pathology at study initiation
- Pregnant or breastfeeding women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Sham Comparator: Sham
The double-blind is used during the first 2 weeks.
From week 3 and on, the study becomes open label.
Subjects in Group I (active MeRT treatment group) will continue receive active MeRT treatment for W3/4; subjects in Group II (placebo/sham group) will receive active MeRT treatment from W3 to W6 for 4 weeks.
All subjects will receive 4 weeks active MeRT treatment.
The study ends in 8th wk.
The data collection points are baseline, weeks of 2, 4, 6, and 8.
The data from weeks 1-2 (Phase I) will be utilized to analyze the safety and any effect of MRT procedure may have over placebo.
The data from weeks 3 on (Phase II) will be used to address if any benefit of longer MeRT treatment (4 vs 2 weeks).
The study design offers both groups 4 weeks of the experimental therapy in a row.
This will provide potentially equal benefit to those participants assuming that MeRT helps to improve PTSD symptoms.
|
Other Names:
|
Experimental: Treatment
The double-blind is used during the first 2 weeks.
From week 3 and on, the study becomes open label.
Subjects in Group I (active MeRT treatment group) will continue receive active MeRT treatment for W3/4; subjects in Group II (placebo/sham group) will receive active MeRT treatment from W3 to W6 for 4 weeks.
All subjects will receive 4 weeks active MeRT treatment.
The study ends in 8th wk.
The data collection points are baseline, weeks of 2, 4, 6, and 8.
The data from weeks 1-2 (Phase I) will be utilized to analyze the safety and any effect of MRT procedure may have over placebo.
The data from weeks 3 on (Phase II) will be used to address if any benefit of longer MeRT treatment (4 vs 2 weeks).
The study design offers both groups 4 weeks of the experimental therapy in a row.
This will provide potentially equal benefit to those participants assuming that MeRT helps to improve PTSD symptoms.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The outcome will be measured by PTSD checklist -- military version (PCL-M) scoring criteria for PTSD. The outcome is measured additionally by Cognitive and Physical Functioning Questionnaire (CPFQ) for cognitive function improvement among the subjects.
Time Frame: At the end of week of 4 and 8.
|
The change of PCL-M and CPFQ scores from baseline and at weeks of 4 and 8 are assessed.
|
At the end of week of 4 and 8.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2015
Primary Completion (Actual)
May 28, 2018
Study Completion (Actual)
May 28, 2018
Study Registration Dates
First Submitted
June 23, 2016
First Submitted That Met QC Criteria
July 1, 2016
First Posted (Estimate)
July 6, 2016
Study Record Updates
Last Update Posted (Actual)
January 2, 2020
Last Update Submitted That Met QC Criteria
December 28, 2019
Last Verified
December 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FWH20150038H
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post-Traumatic Stress Disorders
-
University of California, Los AngelesDefense Advanced Research Projects Agency; Defense Group, Inc.CompletedPost-traumatic Stress Disorder | Post-Traumatic Stress Disorder, ChronicUnited States
-
Oregon Health and Science UniversityNational Center for Complementary and Integrative Health (NCCIH); Oregon Clinical...CompletedPost-Traumatic Stress DisordersUnited States
-
US Department of Veterans AffairsEmory UniversityWithdrawnPost-Traumatic Stress Disorders
-
University of KonstanzGerman Research Foundation; NGO vivo e.V.; GTZ-German Technical Cooperation,... and other collaboratorsCompletedPost-Traumatic Stress DisordersSri Lanka
-
University of California, Los AngelesRecruitingPost-traumatic Stress Disorder | Post-Traumatic Stress Disorder in ChildrenUnited States
-
University of UtahEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedPost-Traumatic Stress Disorder in Children | Post-Traumatic Stress Disorder in AdolescenceUnited States
-
Weill Medical College of Cornell UniversityCompletedPost-traumatic Stress Disorder | Complex Post-Traumatic Stress DisorderUnited States
-
University Hospital, LilleNot yet recruiting
-
Steinn SteingrimssonRecruiting
-
Direction Centrale du Service de Santé des ArméesRecruitingPost-traumatic Stress DisorderFrance
Clinical Trials on individualized Transcranial Magnetic Stimulation
-
Qiuyou XieRecruitingTranscranial Magnetic Stimulation | Disorder of ConsciousnessChina
-
University of California, San DiegoNational Institutes of Health (NIH)RecruitingMajor Depressive DisorderUnited States, Australia
-
University Hospital, Strasbourg, FranceTerminated
-
State University of New York - Upstate Medical...RecruitingHeadache | Brain Concussion | Mild Traumatic Brain Injury | Post-Concussion SymptomsUnited States
-
George Mason UniversityMedStar National Rehabilitation NetworkCompletedStroke | Stroke, Ischemic | Hemiparesis | Cerebral Vascular AccidentUnited States
-
Russian Academy of Medical SciencesCompletedStrokeRussian Federation
-
Samsung Medical CenterTerminatedHealthy Aging | Healthy AdultsKorea, Republic of
-
Centre hospitalier de l'Université de Montréal...Canadian Institutes of Health Research (CIHR)RecruitingMajor Depressive DisorderCanada
-
University Hospital TuebingenFederal Ministry of Health, Germany; University of Ulm; Department of Psychiatry... and other collaboratorsRecruitingMajor Depressive DisorderGermany
-
VA Office of Research and DevelopmentRecruitingDepression | Gulf War IllnessUnited States